Table 2.

Multivariable analyses of treatment group and stratification factors and their associations with overall survival and time to progression^*

	Overall survival		Time to progression
Factor	HR (95% CI)	P†	HR (95% CI)	P†
Treatment group
AE-941    vs placebo	0.95 (0.75 to 1.20)	.65	1.06 (0.81 to 1.38)	.70
Stage
IIIB vs IIIA	1.13 (0.89 to 1.43)	.31	1.05 (0.80 to 1.39)	.72
Chemotherapy   regimen
Carboplatin    vs cisplatin	1.20 (0.94 to 1.52)	.14	1.17 (0.89 to 1.55)	.27
Sex
Male vs female	1.04 (0.82 to 1.32)	.76	1.31 (0.98 to 1.74)	.07

^*Multivariable Cox proportional hazards model adjusted for treatment group, stage, chemotherapy regimen, and sex. CI = confidence interval; HR = hazard ratio.

^†P values (two-sided) were calculated using the Wald test under the Cox proportional hazards model.